Search research articles
Contact Us
Filters
Showing results (91-100 of 103) with videos related to
Page
of 11
Sort By:
The Biochemical Journal
|
October 14, 2022
Regulation of CHK1 inhibitor resistance by a c-Rel and USP1 dependent pathway
Jill E Hunter, Amy E Campbell, Nicola L Hannaway, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 30, 2012
CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs
Mike I Walton, Paul D Eve, Angela Hayes, et al.
Chembiochem : a European Journal of Chemical Biology
|
July 7, 2023
A Degron Blocking Strategy Towards Improved CRL4<sup>CRBN</sup> Recruiting PROTAC Selectivity
Habib Bouguenina, Andrea Scarpino, Jack A O'Hanlon, et al.
Bioorganic & Medicinal Chemistry Letters
|
December 20, 2008
DNA gyrase (GyrB)/topoisomerase IV (ParE) inhibitors: synthesis and antibacterial activity
Stephen P East, Clara Bantry White, Oliver Barker, et al.
Bioorganic & Medicinal Chemistry Letters
|
August 4, 2014
Discovery and in vivo evaluation of alcohol-containing benzothiazoles as potent dual-targeting bacterial DNA supercoiling inhibitors
James T Palmer, Lorraine C Axford, Stephanie Barker, et al.
Iscience
|
April 22, 2024
Erratum: iTAG an optimized IMiD-induced degron for targeted protein degradation in human and murine cells
Habib Bouguenina, Stephanos Nicolaou, Yann-Vaï Le Bihan, et al.
Oncotarget
|
August 22, 2015
The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma
Mike I Walton, Paul D Eve, Angela Hayes, et al.
Iscience
|
June 26, 2023
iTAG an optimized IMiD-induced degron for targeted protein degradation in human and murine cells
Habib Bouguenina, Stephanos Nicolaou, Yann-Vaï Le Bihan, et al.
Journal of Medicinal Chemistry
|
November 25, 2011
Structure-guided evolution of potent and selective CHK1 inhibitors through scaffold morphing
John C Reader, Thomas P Matthews, Suki Klair, et al.
Journal of Medicinal Chemistry
|
May 12, 2016
Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737)
James D Osborne, Thomas P Matthews, Tatiana McHardy, et al.
Page
of 11
Search research articles
Search
Showing results (91-100 of 103) with videos related to
Sort By:
Page
of 11
The Biochemical Journal
|
October 14, 2022
Regulation of CHK1 inhibitor resistance by a c-Rel and USP1 dependent pathway
Jill E Hunter, Amy E Campbell, Nicola L Hannaway, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 30, 2012
CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs
Mike I Walton, Paul D Eve, Angela Hayes, et al.
Chembiochem : a European Journal of Chemical Biology
|
July 7, 2023
A Degron Blocking Strategy Towards Improved CRL4<sup>CRBN</sup> Recruiting PROTAC Selectivity
Habib Bouguenina, Andrea Scarpino, Jack A O'Hanlon, et al.
Bioorganic & Medicinal Chemistry Letters
|
December 20, 2008
DNA gyrase (GyrB)/topoisomerase IV (ParE) inhibitors: synthesis and antibacterial activity
Stephen P East, Clara Bantry White, Oliver Barker, et al.
Bioorganic & Medicinal Chemistry Letters
|
August 4, 2014
Discovery and in vivo evaluation of alcohol-containing benzothiazoles as potent dual-targeting bacterial DNA supercoiling inhibitors
James T Palmer, Lorraine C Axford, Stephanie Barker, et al.
Iscience
|
April 22, 2024
Erratum: iTAG an optimized IMiD-induced degron for targeted protein degradation in human and murine cells
Habib Bouguenina, Stephanos Nicolaou, Yann-Vaï Le Bihan, et al.
Oncotarget
|
August 22, 2015
The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma
Mike I Walton, Paul D Eve, Angela Hayes, et al.
Iscience
|
June 26, 2023
iTAG an optimized IMiD-induced degron for targeted protein degradation in human and murine cells
Habib Bouguenina, Stephanos Nicolaou, Yann-Vaï Le Bihan, et al.
Journal of Medicinal Chemistry
|
November 25, 2011
Structure-guided evolution of potent and selective CHK1 inhibitors through scaffold morphing
John C Reader, Thomas P Matthews, Suki Klair, et al.
Journal of Medicinal Chemistry
|
May 12, 2016
Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737)
James D Osborne, Thomas P Matthews, Tatiana McHardy, et al.
Page
of 11